Unknown

Dataset Information

0

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.


ABSTRACT: Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRASG12C, and inhibits KRAS-dependent signaling. MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) KRASG12C-positive cell line- and patient-derived xenograft models from multiple tumor types, and objective responses have been observed in patients with KRASG12C-positive lung and colon adenocarcinomas. Comprehensive pharmacodynamic and pharmacogenomic profiling in sensitive and partially resistant nonclinical models identified mechanisms implicated in limiting antitumor activity including KRAS nucleotide cycling and pathways that induce feedback reactivation and/or bypass KRAS dependence. These factors included activation of receptor tyrosine kinases (RTK), bypass of KRAS dependence, and genetic dysregulation of cell cycle. Combinations of MRTX849 with agents that target RTKs, mTOR, or cell cycle demonstrated enhanced response and marked tumor regression in several tumor models, including MRTX849-refractory models. SIGNIFICANCE: The discovery of MRTX849 provides a long-awaited opportunity to selectively target KRASG12C in patients. The in-depth characterization of MRTX849 activity, elucidation of response and resistance mechanisms, and identification of effective combinations provide new insight toward KRAS dependence and the rational development of this class of agents.See related commentary by Klempner and Hata, p. 20.This article is highlighted in the In This Issue feature, p. 1.

SUBMITTER: Hallin J 

PROVIDER: S-EPMC6954325 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.

Hallin Jill J   Engstrom Lars D LD   Hargis Lauren L   Calinisan Andrew A   Aranda Ruth R   Briere David M DM   Sudhakar Niranjan N   Bowcut Vickie V   Baer Brian R BR   Ballard Joshua A JA   Burkard Michael R MR   Fell Jay B JB   Fischer John P JP   Vigers Guy P GP   Xue Yaohua Y   Gatto Sole S   Fernandez-Banet Julio J   Pavlicek Adam A   Velastagui Karen K   Chao Richard C RC   Barton Jeremy J   Pierobon Mariaelena M   Baldelli Elisa E   Patricoin Emanuel F EF   Cassidy Douglas P DP   Marx Matthew A MA   Rybkin Igor I II   Johnson Melissa L ML   Ou Sai-Hong Ignatius SI   Lito Piro P   Papadopoulos Kyriakos P KP   Jänne Pasi A PA   Olson Peter P   Christensen James G JG  

Cancer discovery 20191028 1


Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRAS<sup>G12C</sup> inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in GDP-bound KRAS<sup>G12C</sup>, and inhibits KRAS-dependent signaling. MRTX849 demonstrated pronounced tumor regression in 17 of 26 (65%) KRAS<sup>G12C</sup>-positive cell line- and patient-derived xenograft models from multiple tumor typ  ...[more]

Similar Datasets

| S-EPMC10142471 | biostudies-literature
| S-EPMC8405631 | biostudies-literature
| S-EPMC9105196 | biostudies-literature
| S-EPMC9945252 | biostudies-literature
2018-01-24 | GSE103021 | GEO
| S-EPMC9814377 | biostudies-literature
| S-EPMC9299537 | biostudies-literature
| S-EPMC10308767 | biostudies-literature
| S-EPMC10705448 | biostudies-literature
| S-EPMC7795113 | biostudies-literature